- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell...
Hence then, the article about xpovio receives reimbursement approval in south korea for a second multiple myeloma indication was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication )
Also on site :
- Aldi's Boho Accent Table Is a Small Space Game Changer
- Cherie DeVaux se convierte en la primera entrenadora en ganar el Derby de Kentucky con la histórica victoria de Golden Tempo
- Greece rejects Ukraine’s terms for naval drone deal – media